Based on our aim of "make genome editing easier!" and continuous innovation, Ubigene officially initiated the "Red Cotton™ Gene Knockout Project", relying on the improved CRISPR-U™ technology, Ubigene-developed Red Cotton™ CRISPR Gene Editing System, and High-throughput KO Plasmid Construction Platform.
This project was initiated to construct the most resource rich and well-established gene KO resource bank worldwide, with the aim of providing superior resource sharing and more specialized technical services for basic research, drug R & D, disease diagnosis, treatment and evaluation in biomedical fields.
KO Cell Line Bank
gRNA Plasmid Bank
We plan to expand the KO cell line resources of the KO cell line bank to 5000 within next 3-5 years.
The construction of KO cell line bank is a key project of Ubigene's "Red Cotton™ Gene Knockout Project". At present, we have preliminarily constructed a KO cell line bank, with more than 600 KO cell lines in-stock covering 10 research fields; We plan to expand the KO cell line resources of the KO cell line bank to 5000 within next 3-5 years.
To enable the KO Cell Line Bank has more promising applications, Ubigene combined bioinformatics technology with big data analysis technology to sort the cell lines and genes, and construct the customized KO cell line project with two main lines --signaling pathways and disease types:
In order to facilitate the research of signaling pathways, Ubigene has screened 8 popular signaling pathways including NF-kB, Hedgehog, JAK-STAT, MAPK, Notch, PI3K-Akt, TGF-beta, and Wnt and their relevant key genes (over 900 genes). We plan to construct more than 1700 KO cell lines.
Note: the gene list would be appropriately updated according to the research progress and research focus in each field.
Screening of biological targets is the first stage for drug development. After target screening, it is necessary to establish a model for the evaluation of its effect. Generally, in vitro methods can be used to evaluate the activity at the molecular level, cell level or isolated organs, and then in vivo tests can be carried out on this basis. In order to assist the target verification in the process of drug R&D, Ubigene launched Gene Knockout Project with 11 fields of drug targets, covering nearly 400 genes.
| Type | Gene | Gene ID | Species |
In order to help with the research of disease discovery and treatment, we have screened 10 types of popular cell lines and nearly 900 genes, covering 8 human systems and nearly 100 diseases, and we plan to construct more than 2700 KO cell lines.
Note: the gene list would be appropriately updated according to the research progress and research focus in each field.
scale of KO cell bank to achieve the goal of ＞25000 gRNA plasmids within next 3-5 years.
As the basis of the "Red Cotton™ Gene Knockout Project", the Red Cotton™ gRNA Plasmid Bank has more than 10000 gRNA KO plasmids, and will continue to expand the scale of KO cell bank to achieve the goal of ＞25000 gRNA plasmids within next 3-5 years.
Based on our CRISPR-U™ Technology and thousands of gene-editing success cases, Ubigene has successfully developed a series of gRNA plasmids with high gene-editing efficiency. Ubigene's plasmids can enter cells via regular transfection methods and can edit target sites efficiently after transient expression of high levels of Cas9 protein in target cells. Also, our plasmids can be co-transfected with a variety of gRNAs to target multiple sites in cells, which can be widely used in different fields of gene-editing research.
Ubigene's Red Cotton™ CRISPR Gene Editing Designer has been used more than 40000 times, which successfully designed more than 30000 CRISPR gene KO strategies, and our Red Cotton™CRISPR Gene Editing Designer has successfully solved problems for thousands of researchers.
Click here to get more information >
Ubigene has successfully modified over 5000 genes from more than 100 cell lines with our developed CRISPR-U™ technology, and the KO efficiency leaps to 80%, and has higher homologous recombination efficiency. It can easily complete KO, point mutation and KI.
Click here to get more information >
With 12 years of experience, Ubigene has exclusively innovated and developed 6 product lines, including Monoclone Validation Kit (extraction free), Wild-type Cell Lines, Stable Cell Lines (Cas9, Luciferase), Transfection Culture Medium, Over 10,000 in-stock gRNA plasmids, Cas9/GFP/mCherry/Luciferase expression Lentivirus, Mycoplasma Treatment Kit, which fully covers the experiment process of gene-editing in order to simplify the experiment process and improve the efficiency of gene-editing. Make genome editing easier!
Click here to get more information >
Subscribe Us
Make genome editing easier
